Clinical trials: Adalimumab
Psoriatic Arthritis
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)
This study includes two periods. The main objective of Period 1 is to compare the efficacy of upadacitinib 15 mg once daily (QD) and 30 mg QD versus placebo and versus adalimumab (Humira®) in participants with moderately to…
- Trial name
- SELECT - PsA 1 (NCT03104400)
- Testing
- Adalimumab, Upadacitinib
- Where
- 345 sites in United States, Argentina and 44 more
- Volunteers
- 1,705 people
- Sponsor
- AbbVie
Plaque Psoriasis
A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate
This study will compare how well adalimumab works versus methotrexate (MTX) in children with moderate to severe psoriasis in the short term.
- Trial name
- NCT01251614
- Testing
- Adalimumab, Methotrexate
- Volunteers
- 114 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis
Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease
The purpose of this study was to determine how effective and safe the study drug Olokizumab was in patients with Rheumatoid Arthritis (RA) who had been already receiving but not fully responding to treatment with methotrexate…
- Trial name
- CREDO 2 (NCT02760407)
- Testing
- Olokizumab 64mg q4w, Olokizumab 64mg q2w, Adalimumab 40mg q2w
- Where
- 203 sites in United States, Argentina and 16 more
- Volunteers
- 1,648 people
- Sponsor
- R-Pharm International, LLC
Psoriasis
Evaluation of Humira Retention Rate in Psoriasis Patients in Daily Practice and Assessment of Work Productivity and Quality of Life
This observational study will document to what extent in daily clinical practice Humira (adalimumab) therapy is continued, interrupted or permanently discontinued during a follow-up period of 2 years.
- Trial name
- NCT01169987
- Volunteers
- 191 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Arthritis, Rheumatoid
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
Primary Objective: The primary objective of this trial is to establish an equivalence in efficacy between BI 695501 and US-licensed Humira® in patients with active Rheumatoid arthritis based on a statistical comparison of the…
- Trial name
- NCT02137226
- Testing
- BI 695501, US-licensed Humira®
- Where
- 138 sites in United States, Bulgaria and 13 more
- Volunteers
- 645 people
- Sponsor
- Boehringer Ingelheim
Crohn's Disease
Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease
The purpose of this study is to investigate the efficacy, safety, and pharmacokinetics of adalimumab following subcutaneous (SC) administration of 2 dosing regimens in Chinese subjects with Crohn's disease.
- Trial name
- NCT02015793
- Testing
- Adalimumab
- Volunteers
- 30 people
- Sponsor
- AbbVie
Healthy Subjects
MSB11022 in Healthy Subjects
This is a phase I, randomized, double-blind, parallel-group trial to compare Investigation Medicinal Product (IMP) MSB11022, US- Reference Product (RP), and EU- Reference Medicinal Product (RMP) (Humira®) in healthy subjects.
- Trial name
- NCT03014947
- Testing
- MSB11022, US-licensed Humira, EU-approved Humira
- Volunteers
- 237 people, healthy volunteers welcome
- Sponsor
- Fresenius Kabi SwissBioSim GmbH
Rheumatoid Arthritis
Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid Arthritis
Multicenter Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Active Rheumatoid Arthritis
- Trial name
- ReAct (NCT00650026)
- Testing
- adalimumab
- Sponsor
- Abbott
Crohn's Disease
Observational Study Evaluating the Effectiveness of Drug Concentration to Predict the Recapture of Response in Crohn's Disease Patients With Loss of Response ( PRADA )
This is a multi-center study that explores the relationship between recapture of response with escalation to weekly adalimumab and trough adalimumab concentration before escalation in patients experiencing lack of response (LOR).
- Trial name
- PRADA (NCT02896985)
- Where
- 24 sites in Canada
- Volunteers
- 98 people
- Sponsor
- AbbVie
Rheumatoid Arthritis, Ankylosing Spondylitis
Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice
The purpose of this non-interventional, multicenter, post-marketing observational study (PMOS) was to assess rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), plaque psoriasis (PS), Crohn's…
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Crohn´s Disease
- Trial name
- Adherence (NCT01768858)
- Testing
- Adalimumab
- Volunteers
- 96 people
- Sponsor
- AbbVie
Osteoarthritis, Knee
Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab (OKINADA)
This is a Canadian randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the clinical efficacy and safety of adalimumab versus placebo when used to treat subjects with a diagnosis of osteoarthritis…
- Trial name
- OKINADA (NCT02471118)
- Testing
- Adalimumab 40 mg
- Where
- 7 sites in Canada
- Volunteers
- 62 people
- Sponsor
- CARE ARTHRITIS LTD.
Rheumatoid Arthritis
Study of Adalimumab Administered as Subcutaneous Injections in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate
A Randomized, Double-Blind, Placebo-Controlled, Study of the Adalimumab Administered as Subcutaneous Injections in Adult Chinese Rheumatoid Arthritis Subjects Treated with Methotrexate
- Trial name
- NCT00647920
- Testing
- adalimumab
- Where
- Taiwan
- Volunteers
- 47 people
- Sponsor
- Abbott
Psoriasis
Real-World Outcome of Psoriasis Subjects in Korea on Adalimumab
The objective of this non-interventional, observational study is to assess the effect of adalimumab on health-related quality of life in participants with Psoriasis in Korea.
- Trial name
- RAPSODI (NCT03099083)
- Where
- 12 sites in South Korea
- Volunteers
- 97 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
A Study of Adalimumab When Added to Inadequate Standard Anti-rheumatic Therapy in Patients With Active Rheumatoid Arthritis
A total of 100 participants diagnosed with active rheumatoid arthritis were enrolled at 5 sites in Russia. Adalimumab was administered by subcutaneous injection every other week, with dose escalation to weekly dosing available…
- Trial name
- NCT01231321
- Testing
- adalimumab
- Where
- 5 sites in Russia
- Volunteers
- 100 people
- Sponsor
- Abbott
Rheumatoid Arthritis, Psoriatic Arthritis
A Belgian Registry of HUMIRA® (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis ( ProAct )
This is a five year, post-marketing observational study to follow-up patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis who are treated with HUMIRA (adalimumab).
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis
- Trial name
- ProAct (NCT01078558)
- Volunteers
- 5,940 people
- Sponsor
- AbbVie (prior sponsor, Abbott)